• Exclusive distributorships secured for Alberta and British Columbia
• Remplir to be launched at the American Society for Surgery of the Hand (ASSH) conference in Vancouver
• Canadian distributor has expertise in nerve, spine and orthopaedic implant distribution

Orthocell Limited (ASX: OCC) has announced the appointment of its first Canadian distributor for Remplir, the company's groundbreaking nerve repair and regeneration device. Exclusive distributorships have been secured for Alberta and British Columbia, with further appointments anticipated for additional provinces to ensure broad Canadian market coverage. The newly appointed Canadian distributor brings a wealth of expertise in nerve, spine, and orthopaedic implant distribution, with established networks across both urban and rural areas providing comprehensive coverage and accessibility for healthcare providers. The distribution team includes five dedicated sales representatives supported by a network of sub-agents, providing direct engagement with surgeons and hospitals throughout Alberta and BC. Approval processes for individual hospitals will be initiated immediately to facilitate swift market entry. Remplir will be promoted in Canada using the same robust medical education and scientific data that has underpinned the rollout currently underway in the United States. Orthocell's existing in-house US-based Marketing and Medical Education teams will oversee the Canadian market entry and will be in attendance at the upcoming ASSH conference in Vancouver for the in-country market launch. Orthocell received a Medical Device Licence (MDL) from Health Canada for Remplir in April 2025, well ahead of initial expectations, following the lodgement of the regulatory submission in February 2025.

Orthocell expects to see early surgical cases commence in Canada late this year, with market uptake expected to grow into 2026.

With circa $27.5 million in cash and no debt, Orthocell is well-positioned to drive rapid product adoption to deliver a step change in revenue in FY26. Remplir rollout in the US$1.6 Billion US market continues to build momentum, with in-country representatives making significant progress working with distributors to gain hospital approvals, on-board surgeons and establish active accounts.